Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Amarin, Elan deal

The companies restructured AMRN's $46.5 million in debt obligations to ELN. AMRN may pay $30 million in cash no later than Dec. 31, and

Read the full 245 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE